Effects of luseogliflozin, a sodium–glucose co‐transporter 2 inhibitor, on 24‐h glucose variability assessed by continuous glucose monitoring in J apanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled, crossover study

Citations Over TimeTop 10% of 2015 papers

Abstract

The aim of the present study was to determine the effects of luseogliflozin on 24-h glucose levels, assessed by continuous glucose monitoring, and on pharmacodynamic variables measured throughout the day. In this double-blind, placebo-controlled, crossover study, 37 patients with type 2 diabetes mellitus inadequately controlled with diet and exercise were randomized into two groups. Patients in each group first received luseogliflozin then placebo for 7 days each, or vice versa. After 7 days of treatment, the mean 24-h glucose level was significantly lower with luseogliflozin than with placebo [mean (95% confidence interval) 145.9 (134.4-157.5) mg/dl vs 168.5 (156.9-180.0) mg/dl; p < 0.001]. The proportion of time spent with glucose levels ≥70 to ≤180 mg/dl was significantly greater with luseogliflozin than with placebo [median (interquartile range) 83.2 (67.7-96.5)% vs 71.9 (46.9-83.3)%; p < 0.001] without inducing hypoglycaemia. The decrease in glucose levels was accompanied by reductions in serum insulin levels throughout the day.

Related Papers

• → Continuous Glucose Monitoring in Children with Type 1 Diabetes(2007)128 cited
• → Continuous glucose monitoring(2010)33 cited
• → Use of continuous glucose monitoring in young children with type 1 diabetes: implications for behavioral research(2010)22 cited
• USE OF CONTINUOUS GLUCOSE MONITORING (CGM) TRENDS TO PREVENT HYPOGLYCAEMIA DURING EXERCISE IN YOUNG CHILDREN WITH TYPE 1 DIABETES(2018)
• → 955-P: Evaluating Early Initiation of Continuous Glucose Monitoring (CGM) among Youth Diagnosed with Type 1 Diabetes (T1D)(2019)